
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning
2026-11-20 15:00:37Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock, trading close to its 52-week high, has outperformed its sector and broader indices, reflecting growing investor confidence amid shifting market dynamics.
Read More
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning
2026-11-20 14:00:21Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling a shift in market sentiment and positioning. The stock’s recent outperformance relative to its sector and the broader Sensex, combined with increased futures and options activity, suggests investors are taking fresh directional bets amid a backdrop of strong technicals and improving fundamentals.
Read More
Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Positioning
2026-11-20 13:00:21Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent performance, coupled with rising volumes and improved technical positioning, suggests a cautiously optimistic outlook for this mid-cap pharmaceutical player.
Read More
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning
2026-11-20 12:00:18Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling a shift in market sentiment and positioning. The stock’s open interest rose by 11.4% to 45,940 contracts, up from 41,240, accompanied by robust volume activity and a price performance that outpaced its sector peers. This development suggests increased directional bets and heightened investor interest in the mid-cap pharmaceutical player.
Read More
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Mixed Market Signals
2026-11-19 15:00:48Glenmark Pharmaceuticals Ltd. has witnessed a notable 13.2% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the surge in open interest alongside rising volumes suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector.
Read More
Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals
2026-11-19 14:00:32Glenmark Pharmaceuticals Ltd. has witnessed a notable 10.9% increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a slight dip in the stock price, the surge in open interest alongside rising delivery volumes suggests a complex interplay of bullish and cautious sentiment among traders.
Read More
Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Positive Price Momentum
2026-11-18 15:00:38Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling a potential shift in market positioning and investor sentiment. The stock outperformed its sector and reversed a four-day decline, supported by robust volume and price action near its 52-week high.
Read More
Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Positive Market Momentum
2026-11-18 14:00:30Glenmark Pharmaceuticals Ltd. has witnessed a notable 15.0% surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. This rise accompanies a positive price movement, with the stock closing just 1.87% below its 52-week high, outperforming its sector and reversing a four-day losing streak.
Read More
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Positive Market Momentum
2026-11-18 13:00:19Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.05% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a positive price trend, with the stock trading close to its 52-week high and outperforming its sector peers, suggesting renewed bullish sentiment in the mid-cap pharmaceutical stock.
Read MoreAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
17-Nov-2026 | Source : BSEIchnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16-Nov-2026 | Source : BSEGlenmark Pharmaceuticals Inc. USA Launches Authorised Generic of INLYTA (axitinib) Tablets 1 mg and 5mg
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
09-Nov-2026 | Source : BSETranscript of the Earnings Call
Corporate Actions
No Upcoming Board Meetings
Glenmark Pharmaceuticals Ltd. has declared 250% dividend, ex-date: 31 Aug 26
Glenmark Pharmaceuticals Ltd. has announced 1:2 stock split, ex-date: 10 Sep 07
No Bonus history available
No Rights history available